Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

British Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2003, Pages 94-99

  Cooper, Kelvin J ^a   Martin, Paul D ^a   Dane, Aaron L ^a   Warwick, Mike J ^a   Raza, Ali ^a   Schneck, Dennis W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CYP3A4; Ketoconazole; P glycoprotein; Rosuvastatin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; ROSUVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FLUOROBENZENES; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES;

EID: 0037239230     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01720.x     Document Type: Article

References (21)

1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88: 504-508.
2. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin -a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; in press.
3. Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J Clin Pharmacol 2000; 40: 1056 [Abstr. 48].
4. McCormick AD, McKillop D, Butters CJ et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in humanin vitro systems. J Clin Pharmacol 2000;40: 1055 [Abstr. 46].
5. Michniewicz BM, Black AE, Sinz MW, Woolf TF.In vitro andin vivo metabolism of atorvastatin (CI-981) l. ISSX Proc 1994;6: 93.
6. Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans (SBT) identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25: 1191-1199.
7. Jacobsen W, Kirchner G, Hallensleben K et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27: 173-179.
8. Siedlik PH, Olson SC, Yang B-B, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999;39: 501-504.
9. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68: 391-400.
10. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64: 58-65.
11. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64: 177-182.
12. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63: 332-341.
13. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46: 49-53.
14. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60: 54-61.
15. Albengres E, Le Louët H, Tillement J-P. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18: 83-97.
16. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 2000;38: 111-180.
17. Nezasa K, Takeuchi M, Yukawa T et al. Tissue specific distribution of S-4522, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to the liver in rats l. Xenobiotic Metab Dispos 1998;13 (Suppl): S226.
18. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C l. Atheroscler Suppl 2001;2: 90 (P174).
19. Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B Biomed Appl 2002; in press.
20. Tucker GT, Houston JB, Huang S-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Br J Clin Pharmacol 2001;52: 107-117.
21. Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers l. Pharmacotherapy 2001;21: 1255.